Collagen and use thereof

Through the screening and preparation of recombinant humanized collagen through synthetic biological and structural biology technology, the problems of immunogenic reaction and production complexity of existing collagen materials in cartilage repair are solved, and efficient and safe cartilage repair effect is achieved.

WO2024234609A1PCT designated stage expired Publication Date: 2024-11-21SHANXI JINBO BIO PHARMACEUTICAL CO LTD

Patent Information

Application Number
PCT/CN2023/134277
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-12
Filing Date
2023-11-27
Publication Date
2024-11-21

AI Technical Summary

Technical Problem

The existing collagen materials used for cartilage repair have immunogenic reactions, complex and unstable production processes, resulting in unsatisfactory treatment results. Patients need to choose artificial joint replacement, which is accompanied by high costs and complication risks.

Method used

Using synthetic biology and structural biology technology, recombinant humanized collagen core functional zones with triple helical structure of human type II collagen were screened, and recombinant humans with type II can be directly injected into the human body through genetic engineering and protein expression technology. Collagen used for cartilage repair.

Benefits of technology

Recombinant Type II humanized collagen with high yield and low immune rejection has excellent cell adhesion effect, simplifies the production process, and improves the efficiency and safety of cartilage repair.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure PCTCN2023134277-FTAPPB-I100001
    Figure PCTCN2023134277-FTAPPB-I100001
  • Figure PCTCN2023134277-FTAPPB-I100002
    Figure PCTCN2023134277-FTAPPB-I100002
  • Figure PCTCN2023134277-FTAPPB-I100003
    Figure PCTCN2023134277-FTAPPB-I100003
Patent Text Reader

Abstract

Provided are collagen and a use thereof. The collagen comprises an N-terminus sequence and a C-terminus sequence, wherein the N-terminal sequence comprises one or more repeat units, and the repeat units comprise an amino acid sequence as shown in SEQ ID NO. 15. Recombinant type II humanized collagen prepared in the present invention has high activity of promoting cell adhesion, will not cause any immune response when applied to the human body, can be obtained on a large scale, and is expected to be widely applied in the field of cartilage repair.
Need to check novelty before this filing date? Find Prior Art

Description

Collagen and its uses

[0001] This application claims the benefit of priority to Chinese invention patent application No. 202310537499.9, filed May 12, 2023, entitled “Polypeptides and Uses Thereof,” the contents of which are incorporated herein by reference. Technical Field

[0002] The present invention belongs to the field of synthetic biology, and particularly relates to human body structural materials and their biosynthetic preparation methods. Background Art

[0003] Collagen is a type of protein widely distributed in the human body's connective tissue. It is also the most abundant protein in the human body, accounting for 25% to 35% of the total protein. It has been discovered that the human body has at least 28 collagen subtypes, which are located in different tissues and organs.

[0004] Type II collagen, primarily found in cartilage, the vitreous body, and the cornea, is a high-molecular-weight protein. Its filamentous collagen fibers, interwoven with elastin and polysaccharide proteins, form a network-like structure, also known as complex collagen. Type II collagen is essential for cartilage and bone formation, bone growth, and the maintenance of mature cartilage. Therefore, undenatured collagen serves as a structural and functional component of cartilage.

[0005] Type II collagen, as the main component of the articular cartilage matrix, works together with lubricating components such as hyaluronic acid and proteoglycans to protect the cartilage from wear and tear. With age, the synthesis rate of collagen gradually decreases, collagen loss accelerates, articular cartilage degenerates, and friction between bones intensifies, which can cause inflammation in the joints. Currently, the most common treatment for osteoarthritis is to consume collagen, but its protein utilization rate is low, resulting in slow cartilage regeneration, which is not conducive to the patient's recovery and affects the progress and efficiency of treatment. Because current treatment methods are not effective, patients often end up having to choose artificial joint replacement surgery, which is not only expensive but also has the potential for catastrophic complications such as post-operative thrombosis, post-replacement infection, and amputation.

[0006] However, the collagen material currently used as cartilage is mainly derived from animal cartilage extraction. The immunogenicity of animal-derived collagen cannot be eliminated, and the impurity removal and extraction process is still relatively complicated. It is difficult to ensure the triple helix structure of collagen, and it cannot be used for large-scale production.

[0007] At the same time, animal-derived immune responses are also a major reason for the limited application of collagen. As my country's collagen industry continues to grow, the use of biosynthetic pathways to obtain collagen is becoming increasingly mature, especially humanized collagen, which has become a global leader. In 2021, the National Medical Products Administration (NMPA) named and classified biosynthesized collagen. Among them, recombinant humanized collagen refers to the full-length or partial amino acid sequence functional region encoded by a specific type of human collagen gene prepared by DNA recombinant technology, or a combination of functional regions containing human collagen functions.

[0008] The traditional method of producing collagen is to use acid, alkali, and enzymatic hydrolysis to treat animal tissues to extract collagen derivatives. The collagen extracted by these methods has lost its original biological activity and cannot be used in the biomedical field to truly play its role. With the development of modern technology, some extraction methods have emerged at home and abroad to remove impurities and extract animal cartilage through enzymatic hydrolysis to obtain non-denatured type II collagen. Although the collagen produced by these methods can be used for cartilage repair, the impurity removal and extraction time is long, the product purity is low, and the product stability is poor, which is not conducive to large-scale production. In response to the shortcomings of the existing technology, some companies have proposed using Pichia pastoris as a host strain to prepare type II collagen for cartilage repair. However, this collagen is not humanized collagen and therefore has a certain immunogenic reaction.

[0009] Therefore, there is an urgent need for a recombinant humanized type II collagen that can be directly injected into the human body and does not cause an immunogenic response, so that it can be used as a human structural material for cartilage repair.

[0010] Summary of the Invention

[0011] Human structural materials primarily consist of structural proteins, including collagen. These proteins are complex in structure and precise in function, making them crucial for tissue repair and regeneration, but they are difficult to obtain using conventional production methods. This invention utilizes synthetic biology and structural biology techniques to develop a macromolecular functional protein that embodies the triple-helical structure of human type II collagen and performs the functions of human collagen. The inventors conducted a large-scale functional region screening. First, sequence screening identified numerous charged amino acids within the Gly-XY repeats in the helical region of native type II collagen, which interact to bind cells. Therefore, regions lacking these important charge motifs were excluded. Second, computer-assisted protein structure prediction methods were used to identify potential helical functional regions with the highest interchain hydrogen bonding and the strongest ability to stabilize trimer aggregation. Third, using protein expression prediction methods, functional regions of human type II collagen with the highest protein expression, ease of purification, and excellent stability were identified. Fourth, amino acid fragments from these regions were directly linked and optimized by repeating them multiple times (the repeats ensure that the molecular weight of the recombinant humanized type II collagen is within a certain range for ease of purification and stability).

[0012] This invention encompasses the core functional region screening, synthesis process, and application scenarios of recombinant humanized type II collagen. This patented design is the first to invent a functional region screening and protein synthesis process for recombinant humanized type II collagen that can be directly injected into the human body and can be used for cartilage repair.

[0013] The present invention is based in part on the inventors' unexpected discovery that compared to other recombinant humanized type II collagens, recombinant humanized type II collagen HC2B-A10 is expressed in higher amounts when recombinantly expressed, is easier to isolate and purify, and has superior cell adhesion compared to bovine type I collagen.

[0014] In one aspect, the present invention provides a collagen protein or polypeptide comprising a plurality of repeating units comprising the amino acid sequence shown in SEQ ID NO.15 (gtpglpgvkghrgypgldgakgtpglpgvkghrgypgldgak) or a variant thereof having 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity, wherein each repeating unit is directly linked or separated by one or more amino acid residues. In one embodiment, the repeating unit may be an amino acid sequence obtained by mutation (substitution, insertion, deletion, or addition) of the amino acid sequence of SEQ ID NO.15 by one or more amino acid residues.

[0015] In one embodiment, the number of repeating units is 1 to 20. In one embodiment, the number of repeating units is 6 to 10. In one embodiment, the number of repeating units is 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20.

[0016] In one embodiment, the collagen or polypeptide comprises the amino acid sequence shown in SEQ ID NO.10. In one embodiment, the collagen or polypeptide comprises the amino acid sequence shown in SEQ ID NO.10 or the amino acid sequence of SEQ ID NO.3 or 10 obtained by mutation (substitution, insertion, deletion or addition) of one or more amino acid residues, or a variant having 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity with the amino acid sequence shown in SEQ ID NO.10. In one embodiment, when the collagen or polypeptide sequence is mutated, the resulting collagen or polypeptide retains the functions of the present invention, such as the ability of cell adhesion and cartilage repair.

[0017] In one aspect, the present invention provides polynucleotides encoding the collagen proteins or polypeptides described herein.

[0018] In one embodiment, the polynucleotide comprises the nucleotide sequence shown in SEQ ID NO.29.

[0019] In one aspect, the invention provides nucleic acids comprising the polynucleotides described herein. Optionally, the nucleic acids further comprise nucleotides encoding a purification tag, such as a His tag, a GST tag, an MBP tag, a SUMO tag, or a NusA tag. Optionally, the nucleic acids further comprise nucleotides encoding a leader sequence.

[0020] In one aspect, the present invention provides a vector comprising a polynucleotide described herein or a nucleic acid described herein.

[0021] In one embodiment, the vector is an expression vector.In one embodiment, the vector comprises expression control elements, such as a promoter, terminator and / or enhancer, operably linked to the polynucleotide or nucleic acid.

[0022] In one aspect, the invention provides a host cell comprising a polynucleotide as described herein, a nucleic acid as described herein, or a vector as described herein. In one embodiment, the host cell is a bacterial, fungal, or animal cell. In one embodiment, the bacterial cell is Escherichia coli. In one embodiment, the fungus is a yeast, such as Saccharomyces cerevisiae.

[0023] In one aspect, the present invention provides a method for producing the collagen or polypeptide described herein, comprising:

[0024] (1) culturing the host cell described herein under appropriate culture conditions;

[0025] (2) harvesting host cells and / or culture medium containing the collagen or polypeptide; and

[0026] (3) Purification of collagen or polypeptide.

[0027] In one aspect, the present invention provides a composition comprising the collagen or polypeptide described herein. In one embodiment, the composition is a kit. In one embodiment, the composition is one or more of a biological dressing, a human biomimetic material, a plastic surgery material, an organoid culture material, a cardiovascular stent material, a coating material, a tissue injection filler material, an ophthalmic material, a gynecological biomaterial, a nerve repair and regeneration material, a liver tissue material and a vascular repair and regeneration material, a 3D printed artificial organ biomaterial, a cosmetic raw material, a pharmaceutical excipient, and a food additive. In one embodiment, the composition is an injectable composition or an oral composition.

[0028] In one embodiment, the composition is a composition for cartilage repair. In one embodiment, the composition is an injectable composition for cartilage repair.

[0029] In one aspect, the present invention provides a method for increasing cell adhesion, comprising contacting a cell with a collagen or polypeptide described herein, a polynucleotide described herein, a nucleic acid described herein, a vector described herein, a host cell described herein, and / or a composition described herein.

[0030] In one aspect, the present invention provides the use of collagen or polypeptide as described herein, polynucleotides as described herein, nucleic acids as described herein, vectors as described herein, host cells as described herein, and / or compositions as described herein in the preparation of a kit for increasing cell adhesion or cartilage repair. In one aspect, the present invention provides the use of collagen or polypeptide as described herein, polynucleotides as described herein, nucleic acids as described herein, vectors as described herein, host cells as described herein, and / or compositions as described herein in one or more of biological dressings, human biomimetic materials, plastic surgery materials, organoid culture materials, cardiovascular stent materials, coating materials, tissue injection filling materials, ophthalmic materials, obstetrics and gynecology biomaterials, nerve repair and regeneration materials, liver tissue materials and vascular repair and regeneration materials, 3D printing artificial organ biomaterials, cosmetic raw materials, pharmaceutical excipients and food additives.

[0031] Advantages of the present invention include:

[0032] 1. The present invention provides the core functional region and amino acid sequence of recombinant humanized type II collagen.

[0033] 2. This invention successfully synthesized for the first time a recombinant humanized type II collagen that can be injected into the human body for use in cartilage repair.

[0034] 3. The amino acid composition of the recombinant humanized type II collagen produced is 100% identical to the corresponding part of the natural collagen amino acid sequence, and will not cause immune rejection or allergic reactions when applied to the human body.

[0035] 4. The preparation method in this article is simple and can be used to produce high-yield recombinant type II humanized collagen on a large scale.

[0036] 5. In terms of expression, separation and purification effects, compared with other recombinant humanized type II collagens, recombinant type II humanized collagen HC2B-A10 achieved the best effect.

[0037] 6. The recombinant humanized type II collagen of the present invention has more excellent bioadhesive activity, that is, the recombinant humanized type II collagen HC2B-A10 is greater than the bovine type I collagen. BRIEF DESCRIPTION OF THE DRAWINGS

[0038] Figure 1: Crude purity of recombinant humanized type II collagen HC2B-a6 and HC2B-b5;

[0039] Figure 2: Crude purity of recombinant humanized type II collagen HC2B-b1, HC2B-a3, and HC2B-b3;

[0040] Figure 3: Purification of recombinant humanized type II collagen B3Q, HC2B-A8, and HC2B-A7;

[0041] Figure 4: Purification of recombinant humanized type II collagen HC2B-A10 and crude purity of HC2B-B9;

[0042] Figure 5: Purification of recombinant humanized type II collagen HC2B-A9;

[0043] Figure 6: Crude purity of recombinant humanized type II collagen HC2B-B8, HC2B-B7, and HC2B-B10;

[0044] Figure 7: Purification of recombinant humanized type II collagen HC2B-B7 and HC2B-B9;

[0045] Figure 8: Activity detection of recombinant humanized type II collagen HC2B-A10;

[0046] Figure 9: Map of the pET-28a-Trx-His expression vector. DETAILED DESCRIPTION

[0047] To make the objectives, technical solutions, and advantages of the present invention more clear, the technical solutions in the embodiments of the present invention will be clearly and completely described below in conjunction with the embodiments of the present invention. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without making creative efforts shall fall within the scope of protection of the present invention.

[0048] Recombinant collagen is a new type of biomaterial that is screened and prepared using cutting-edge structural biology, genetic engineering and other technologies, using the gene encoding the functional region of a specific type of human collagen as a template, to obtain the same or similar amino acid sequence as human collagen.

[0049] As used herein, "polypeptide" refers to a plurality of amino acid residues linked by peptide bonds. In this article, collagen, recombinant collagen, recombinant humanized type II collagen or polypeptide can be used interchangeably.

[0050] Herein, collagen or polypeptide may comprise one or more repeating units comprising the amino acid sequence shown in SEQ ID NO.15 or the amino acid sequence after mutation (substitution, addition, insertion or deletion) of one or more amino acid residues of the amino acid sequence. The number of repeating units may be 1-20. For example, the number of repeating units is 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20. In particular, the mutation may be a substitution, such as a conservative amino acid substitution. The amino acid sequence of SEQ ID NO.15 is gtpglpgvkghrgypgldgakgtpglpgvkghrgypgldgak. Each repeating unit may be directly connected or spaced apart by one or more amino acid residues.

[0051] When the collagen or polypeptide sequence is mutated or there is a spacer sequence, the resulting collagen or polypeptide retains the functions of the present invention, such as the ability of cell adhesion and cartilage repair.

[0052] The collagen protein or polypeptide of the present invention can be synthesized or can be expressed by recombinant expression. In the case of recombinant expression, the collagen protein or polypeptide of the present invention can be encoded by a polynucleotide. The polynucleotide can be codon-optimized for the host cell in which it is expressed. The polynucleotide encoding the collagen protein or polypeptide can be operably linked to an expression control element, such as a promoter, a terminator and / or an enhancer to form a nucleic acid, or an expression cassette. The nucleic acid can also include nucleotides encoding a purification tag, such as a His tag, a GST tag, an MBP tag, a SUMO tag or a NusA tag, or nucleotides encoding a leader sequence, to facilitate purification or secretion of the collagen protein or polypeptide.

[0053] As used herein, the term "vector" is a nucleic acid delivery vehicle into which a polynucleotide can be inserted. When a vector is capable of expressing a protein encoded by the inserted polynucleotide, the vector is referred to as an expression vector. A vector can be introduced into a host cell by transformation, transduction, or transfection, so that the genetic material elements it carries are expressed in the host cell. Vectors are well known to those skilled in the art and include, but are not limited to, plasmids; phagemids; cosmids; artificial chromosomes, such as yeast artificial chromosomes (YACs), bacterial artificial chromosomes (BACs), or P1-derived artificial chromosomes (PACs); bacteriophages such as lambda phage or M13 phage, and animal viruses. A vector can contain a variety of elements that control expression, including, but not limited to, promoter sequences, transcription initiation sequences, enhancer sequences, selection elements, and reporter genes. In addition, a vector may also contain a replication initiation site. A vector can contain a nucleic acid of the present invention to facilitate introduction into cells for expression. A vector can contain expression control elements, such as a promoter, terminator, and / or enhancer, operably linked to the nucleic acid.

[0054] As used herein, the term "host cell" is a cell into which a nucleic acid molecule has been introduced by molecular biology techniques. These techniques include transfection with viral vectors, transformation with plasmid vectors, and introduction of naked DNA by electroporation, lipofection, and particle gun acceleration. The host cell can be a eukaryotic cell or a prokaryotic cell. For example, a eukaryotic cell is a yeast cell, an animal cell, and / or an insect cell. The prokaryotic cell can be an Escherichia coli cell.

[0055] The present invention also provides a method for producing collagen or polypeptide, comprising: (1) culturing the host cells described herein under suitable culture conditions; (2) harvesting the host cells and / or culture medium containing the collagen or polypeptide; and (3) purifying the collagen or polypeptide. The method of the present invention may include a step of enzymatically cleaving the tag.

[0056] The collagen or polypeptide of the present invention can be prepared into a composition or kit. The composition or kit can be a composition or kit for tissue filling and / or volume expansion. The composition or kit can also contain auxiliary substances. The composition of the present invention can be a cartilage repair agent, which contains the collagen or polypeptide described herein. The composition of the present invention can be injectable. The composition of the present invention can be a structural material for the human body, for example, for cartilage repair, and does not induce an immune response in the human body.

[0057] As used herein, the degree of association between two amino acid sequences or between two nucleotide sequences is described by parameter " sequence identity ".For purposes of the present invention, use as in EMBOSS software package (EMBOSS: European Molecular Biology Open Software Suite, people such as Rice, 2000, Trends Genet. [genetics trend] 16:276-277) (preferred 5.0.0 version or updated version) Ni Deman-Weng Shi algorithm (Needleman and Wunsch, 1970, J.Mol.Biol. [J.Molecular Biology] 48:443-453) determine the sequence identity between two amino acid sequences.The parameter used is gap opening penalty 10, gap extension penalty 0.5 and EBLOSUM62 (EMBOSS version of BLOSUM62) substitution matrix.The output (using non-simplified option to obtain) of Ni Deer, who is labeled as " longest identity ", is used as identity percentage and is calculated as follows:

[0058] (number of identical residues × 100) / (length of alignment - total number of gaps in the alignment)

[0059] For purposes of the present invention, the sequence identity between two deoxynucleotide sequences is determined using the Needleman-Wunsch algorithm (Needleman and Wunsch, 1970, supra) as implemented by the Needleman program of the EMBOSS software package (EMBOSS: European Molecular Biology Open Software Suite, Rice et al., 2000, supra) (preferred 5.0.0 version or later). The parameters used are a gap opening penalty of 10, a gap extension penalty of 0.5, and an EDNAFULL (EMBOSS version of NCBI NUC4.4) substitution matrix. The output of Needleman, labeled "longest identity," (obtained using the non-simplified option), which is labeled "longest identity," is used as percent identity and is calculated as follows:

[0060] (number of identical deoxyribonucleotides x 100) / (length of alignment - total number of gaps in the alignment)

[0061] In this article, the repeating units of the collagen or polypeptide of the present invention or the collagen or polypeptide may have certain mutations. For example, the amino acid sequence of one or more of these parts may have substitutions, deletions, additions or insertions of amino acid residues. In the context of amino acid mutations, "a plurality" can be 2-40, such as 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 31, 32, 33, 34, 35, 36, 37, 38 or 39, or any numerical range therebetween.

[0062] That is, the present invention can use repeat unit variants, as long as the variant retains the activity of promoting cell adhesion. Specifically, the variant can have a certain percentage identity with the specified sequence (any collagen or polypeptide sequence described herein), such as 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% identity. The specified sequence can be any sequence of the present invention, such as SEQ ID NO.1-16, but it is preferred that these variants retain the intended function, such as increasing cell adhesion or cartilage repair.

[0063] Method of the present invention

[0064] In response to current research, the present invention provides a method for biosynthesizing recombinant humanized type II collagen, i.e., a method for preparing a human structural material. The method may include one or more of the following steps: (1) screening of functional regions and construction of bacterial strains; (2) large-scale fermentation and protein expression; and (3) purification and optional enzymatic cleavage of the humanized type II collagen.

[0065] Functional region screening and strain construction can be carried out as follows: (1) large-scale functional region screening to obtain the functional region of the target gene; (2) inserting the obtained functional region of the target gene into the PET-28a-Trx-His expression vector to obtain a recombinant expression plasmid; (3) transferring the recombinant expression plasmid into the Escherichia coli competent cell BL21 (DE3) to screen and obtain positive Escherichia coli genetically engineered bacteria.

[0066] Large-scale biofermentation can be carried out as follows: the positive genetically engineered Escherichia coli obtained by screening is added to a shake flask containing an antibiotic stock solution and cultured in a constant temperature shaker at 220 rpm and 37°C.

[0067] Protein induction expression can be carried out as follows: (1) Cool the shake flask after culture to 16-30°C; (2) Add IPTG mother solution to induce expression; (3) Place the induced bacterial solution in a centrifuge bottle, centrifuge at 6000 rpm and 4°C for 12 minutes, and then collect the bacteria.

[0068] The purification and optional enzymatic cleavage of humanized type II collagen can be carried out as follows: (1) crude purification of humanized type II collagen on a Ni affinity chromatography column; (2) addition of TEV enzyme for enzymatic cleavage in a certain proportion; and (3) fine purification of humanized type II collagen on an ion exchange column.

[0069] The screened functional regions are as follows: (1) amino acid sequence of HC2B-a3: gkpgddgeagkpgkagergppgpqgargfpgtpglpgvkghrgypgldgakgeagapgvkgesgspgengspgpmgprglpgergrtgpagaagargndgqp; (2) amino acid sequence of HC2B-a6: gkpgkagergppgpqgargfpgtpglpgvkghrgkpgkagergppgpqgargfpgtpglpgvkghrgkpgkagergppgpqgargfpgtpglpgvkghrgkpgkagergppgpqgargfpgtpglpgvkghrgkpgkagergppgpqgargfpgtpglpgvkghrgkpgkagergppgpqgargfpgtpglpgvkghrgkpgkagergp pgpqgargfpgtpglpgvkghrgkpgkagerg; (3) Amino acid sequence of HC2B-b1: gepgregspgadgppgrdgaagvkgdrgetgavgapgapgppgspgpagptgkqgdrgeagaqgpmgpsgpagargiqgpqgprgdkgeagepgerglkghrgftglqglpgp pgpsgdqgasgpagpsgprgppgpvgpsgkdgangipgpigppgprgrsgetgpa; (4) HC2B-b3 amino acid sequence: gspgpagptgkqgdrgeagaqgpmgpsgpagargiqgpqgprgdkgeagepgerglkghrgftglqglpgppgpsgdqgasgpagpsgpr;(5) Amino acid sequence of HC2B-b5: gargiqgpqgprgdkgeagepgerglkghrgftglqglpgppgpsgargiqgpqgprgdkgeagepgerglkghrgftglqglpgppgpsgargiqgpqgprgdkgeagepgerglkghrgftglqglpgppgpsgargiqgpqgprgdkgeagepgerglkghrgftglqglpgppgpsgargiqgpqgprgdkgeagepgerglkghrgftglqglpgppgpsgargiqgpqgprgdkgeagepgerglkghrgftglqglpgppgpsgargiqgpqgprgdkgeagepgerglkghrgftglqglpgppgpsgargiqgpqgprgdkgeagepgerglkghrgftglqglpgppgps; (6) Amino acid sequence of B3Q: gspgpagptgkqgdrgeagaqgpmgpsgpagargiqgpqgprgdkgeagepgerglkghrgftglqglpgppgpsgdqgasgpagpsgprgspgpagptgkqgdrgeagaqgpmgpsgpagargiqgpqgprgdkgeagepgerglkghrgftglqglpgppgpsgdqgasgpagpsgprgspgpagptgkqgdrgeagaqgpmgpsgpagargiqgpqgprgdkgeagepgerglkghrgftglqglpgppgpsgdqgasgpagpsgprgspgpagptgkqgdrgeagaqgpmgpsgpagargiqgpqgprgdkgeagepgerglkghrgftglqglpgppgpsgdqgasgpa gpsgpr;(7) Amino acid sequence of HC2B-A7: gpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtcglpgvkghrgypgldgak;(8) Amino acid sequence of HC2B-A8: gargfpgtpglpgvkghrgypgldgakgargfpgtpglpgvkghrgypgldgakgargfpgtpglpgvkghrgypgldgakgargfpgtpglpgvkghrgypgldgakgargfpgtpglpgvkghrgypgldgakgargfpgtpglpgvkghrgypgldgakgargfpgtpglpgvkghrgypgldgakgargfpgtpglpgvkghrgypgldgakgargfpgtpglpgvkghrgypgldgakgargfpgtpglpgvkghrgypgldgakgargfpgtpglpgvkghrgypgldgakgargfpgtpglpgvkghrgypgldgakgargfpgtpglpgvkghrgypgldgakgargfpgtpglpgvkghrgypgldgakgargfpgtpglpgvkghrgypgldgakgargfpgtpglpgvkghrgypgldgakgargfpgtpglpgvkghrgypgldgakgargfpgtpglpgvkghrgypgldgakgargfpgtpglpgvkghrgypgldgakgargfpgtpglpgvkghrgypgldgakgargfpgtpglpgvkghrgypgldgakgargfpgtpglpgvkghrgypgldgakgargfpgtpglpgvkghrgypgldgakgargfpgtpglpgvkghrgypgldgakgargfpgtpglpgvkghrgypgldgakgargfpgtpglpgvkghrgypgldgakgargfpgtpglpgvkghrgypgldgakgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpq(9) Amino acid sequence of HC2B-A9: gfpgtpglpgvkghrgypgldgakgfpgtpglpgvkghrgypgldgakgfpgtpglpgvkghrgypgldgakgfpgtpglpgvkghrgypgldgakgfpgtpglpgvkghrgypgldgakgfpgtpglpgvkghrgypgldgakgfpgtpglpgvkghrgypgldgakgfpgtpglpgvkghrgypgldgakgfpgtpglpgvkghrgypgldgakgfpgtpglpgvkghrgypgldgakgfpgtpglpgvkghrgypgldgakgfpgtpglpgvkghrgypgldgakgfpgtpglpgvkghrgypgldgakgfpgtpglpgvkghrgypgldgakgfpgtpglpgvkghrgypgldgak: (10) Amino acid sequence of HC2B-A10: gtpglpgvkghrgypgldgakgtpglpgvkghrgypgldgakgtpglpgvkghrgypgldgakgtpglpgvkghrgypgldgakgtpglpgvkghrgypgldgakgtpglpgvkghrgypgldgakgtpglpgvkghrgypgldgakgtpglpgvkghrgypgldgakgtpglpgvkghrgypgldgakgtpglpgvkghrgypgldgakgtpglpgvkghrgypgldgakgtpglpgvkghrgypgldgakgtpglpgvkghrgypgldgakgtpglpgvkghrgypgldgakgtpglpgvkghrgypgldgakgtpglpgvkghrgypgldgak;(11) Amino acid sequence of HC2B-B7: gerglkghrgftglqglpgppgpsgdqgasgpagpsgprgerglkghrgftglqglpgppgpsgdqgasgpagpsgprgerglkghrgftglqglpgppgpsgdqgasgpagpsgprgerglkghrgftglqglpgppgpsgdqgasgpagpsgprgerglkghrgftglqglpgppgpsgdqgasgpagpsgprgerglkghrgftglqglpgppgpsgdqgasgpagpsgprgerglkghrgftglqglpgppgpsgdqgasgpagpsgpr; (12) Amino acid sequence of HC2B-B8: gerglkghrgftglqglpgppgpsgdqgasgpagerglkghrgftglqglpgppgpsgdqgasgpagerglkghrgftglqglpgppgpsgdqgasgpagerglkghrgftglqglpgppgpsgdqgasgpagerglkghrgftglqglpgppgpsgdqgasgpagerglkghrgftglqglpgppg psgdqgasgpagerglkghrgftglqglpgppgpsgdqgasgpagerglkghrgftglqglpgppgpsgdqgasgpagerglkghrgftglqglpgppgpsgdqgasgpa;(13) Amino acid sequence of HC2B-B9: gerglkghrgftglqglpgppgpsgdqgerglkghrgftglqglpgppgpsgdqgerglkghrgftglq glpgppgpsgdqgerglkghrgftglqglpgppgpsgdqgerglkghrgftglqglpgppgpsgdqgerglkghrgftglqglpgpp gpsgdqgerglkghrgftglqglpgppgpsgdqgerglkghrgftglqglpgppgpsgdqgerglkghrgftglqglpgppgpsgdq gerglkghrgftglqglpgppgpsgdqgerglkghrgftglqglpgppgpsgdqgerglkghrgftglqglpgppgpsgdq; (14)HC Amino acid sequence of 2B-B10: gerglkghrgftglqglpgppgerglkghrgftglqglpgppgerglkghrgftglqglpgppgerglkghrgf tglqglpgppgerglkghrgftglqglpgppgerglkghrgftglqglpgppgerglkghrgftglqglpgppgerglkghrgftglq glpgppgerglkghrgftglqglpgppgerglkghrgftglqglpgppgerglkghrgftglqglpgppgerglkghrgftglqglp gppgerglkghrgftglqglpgppgerglkghrgftglqglpgppgerglkghrgftglqglpgppgerglkghrgftglqglpgpp. ;

[0070] The amino acid sequence of the recombinant humanized type II collagen prepared by the present invention can be derived from the functional region of natural human type II collagen, including proteins obtained by mutating and modifying the amino acid sequence of the functional region and similar functional regions.

[0071] The recombinant humanized type II collagen prepared by the present invention completely matches the amino acid sequence of human collagen, so it can be directly injected into the human body for cartilage repair without generating immunogenic reactions.

[0072] The present invention provides a collagen protein or polypeptide comprising the amino acid sequence of any one of SEQ ID NOs. 1-14 or an amino acid sequence in which the amino acid sequence has been mutated. The mutation may be a substitution, addition, deletion, or insertion. Preferably, the substitution may be a conservative substitution. The collagen protein or polypeptide of the present invention may be derived from a peptide segment derived from type II human collagen. The collagen protein or polypeptide of the present invention may comprise multiple peptide segments obtained in this manner. The peptide segments may be connected via a linker or directly to form the collagen protein or polypeptide of the present invention. The linker may be one or more amino acid residues. For example, the linker may be a flexible linker commonly used in the art.

[0073] The present invention provides a plurality of repeating units, as shown in the underlined amino acid sequences of the Examples. In particular, the present invention provides repeating units of the amino acid sequence of SEQ ID NO: 15. The collagen or polypeptide of the present invention may comprise a plurality of repeating units, for example, 2-30, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28 or 29.

[0074] Example

[0075] The following examples are provided to illustrate the present invention. It should be understood by those skilled in the art that the examples are merely illustrative and non-limiting. The present invention is limited only by the scope of the appended claims.

[0076] Example 1: Construction and expression of recombinant humanized type II collagen

[0077] 1. Conduct large-scale functional region screening. First, sequence screening is performed. The Gly-XY repeat gene sequence in the helical region of natural type II collagen contains a large number of charged amino acids. These charges bind to cells through interactions, so regions without these important charge motifs are excluded. Second, computer-assisted protein structure prediction methods are used to help screen potential helical functional regions with the most interchain hydrogen bonds and the most stable trimer aggregation form. Third, based on the prediction method of protein expression properties, functional regions of human type II collagen with the highest protein expression, ease of purification, and good stability are screened. Fourth, amino acid fragments in these regions are directly linked and optimized by repeating n times (the repetition is to ensure that the molecular weight of the recombinant humanized type II collagen is within a certain range for easy purification and stability). The following different target gene functional regions of recombinant humanized type II collagen are obtained:

[0078] (1) Amino acid sequence of HC2B-a3: gkpgddgeagkpgkagergppgpqgargfpgtpglpgvkghrgypgldgakgeagapgvkgesgspgengspgpmgprglpgergrtgpagaagargndgqp (SEQ ID NO. 1);

[0079] (2) Amino acid sequence of HC2B-a6: gkpgkagergppgpqgargfpgtpglpgvkghrgkpgkagergppgpqgargfpgtpglpgvkghrgkpgkagergppgpqgargfpgtpglpgvkghrgkpgkagergppgpqgargfpgtpglpgvkghrgkpgkagergppgpqgargfpgtpglpgvkghrgkpgkagergppgpqgargfpgtpglpgvkghrgkpgkagergppgpqgargfpgtpglpgvkghrgkpgkagerg (SEO ID NO. 2, the underlined part is the repeating unit);

[0080] (3) Amino acid sequence of HC2B-b1: gepgregspgadgppgrdgaagvkgdrgetgavgapgapgppgspgpagptgkqgdrgeagaqgpmgpsgpagargi qgpqgprgdkgeagepgerglkghrgftglqglpgppgpsgdqgasgpagpsgprgppgpvgpsgkdgangipgpigppgprgrsgetgpa(SEQ ID NO.3);

[0081] (4) HC2B-b3 amino acid sequence: gspgpagptgkqgdrgeagaqgpmgpsgpagargiqgpqgprgdkgeagepgerglkghrgftglqglpgppgpsgdqgasgpagpsgpr (SEQ ID NO. 4);

[0082] (5) Amino acid sequence of HC2B-b5: gargiqgpqgprgdkgeagepgerglkghrgftglqglpgppgpsgargiqgpqgprgdkgeagepgerglkghrgftglqglpgppgpsgargiqgpq gprgdkgeagepgerglkghrgftglqglpgppgpsgargiqgpqgprgdkgeagepgerglkghrgftglqglpgppgpsgargiqgpqgprgdkgeagepgerglkghrgftglq glpgppgpsgargiqgpqgprgdkgeagepgerglkghrgftglqglpgppgpsgargiqgpqgprgdkgeagepgerglkghrgftglqglpgppgpsgargiqgpqgprgdkgeagepgerglkghrgftglqglpgppgps(SEQ ID NO.5, the underline is the repeating unit part);

[0083] (6) Amino acid sequence of B3Q: gspgpagptgkqgdrgeagaqgpmgpsgpagargiqgpqgprgdkgeagepgerGlkghrgftglqglpgppgpsgdqgasgpagpsgprgspgpagptgkqgdrgeagaqgpmgpsgpagargiqgpqgprgdkgeagepgerglkghrgftglqglpgppgpsgdqgasgpag psgprgspgpagptgkqgdrgeagaqgpmgpsgpagargiqgpqgprgdkgeagepgerglkghrgftglqglpgppgpsgdqgasgpagpsgprgspgpagptgkqgdrgeagaqgpmgpsgpagargiqgpqgprgdkgeagepgerglkghrgftglqglpgppgpsgdqgasgpagpsgpr (SEQ ID NO. 6, the underlined portion is the repeating unit);

[0084] (7) Amino acid sequence of HC2B-A7: gpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgakgpqgargfpgtpglpgvkghrgypgldgak (SEQ ID NO.7, the underlined part is the repeating unit);

[0085] (8) Amino acid sequence of HC2B-A8: gargfpgtpglpgvkghrgypgldgakgargfpgtpglpgvkghrgypgldgakgargfpgtpglpgvkghrgypgldgakgargfpgtpglpgvkghrgypgldgakgargfpgtpglpgvkghrgypgldgakgargfpgtpglpgvkghrgypgldgakgargfpgtpglpgvkghrgypgldgakgargfpgtpglpgvkghrgypgldgakgargfpgtpglpgvkghrgypgldgakgargfpgtpglpgvkghrgypgldgakgargfpgtpglpgvkghrgypgldgakgargfpgtpglpgvkghrgypgldgak (SEQ ID NO.8, the underlined part is the repeating unit);

[0086] (9) Amino acid sequence of HC2B-A9: gfpgtpglpgvkghrgypgldgakgfpgtpglpgVkghrgypgldgakgfpgtpglpgvkghrgypgldgakgfpgtpglpgvkghrgypgldgakgfpgtpglpgvkghrgypgldgakgfpgtpglpgvkghrgypgldgakgfpgtpglpgvkghrgypgldgakgfpgtpglpgvkghrgypgldgakgfpgtpglpgvkghrgypgldgakgfpgtpglpgvkghrgypgldgakgfpgtpglpgvkghrgypgldgakgfpgtpglpgvkghrgypgldgak(SEQ ID NO.9, the underlined part is the repeating unit);

[0087] (10) Amino acid sequence of HC2B-A10: gtpglpgvkghrgypgldgakgtpglpgvkghrgypgldgak

[0088] Gtpglpgvkghrgypgldgakgtpglpgvkghrgypgldgak

[0089] Gtpglpgvkghrgypgldgakgtpglpgvkghrgypgldgak

[0090] Gtpglpgvkghrgypgldgakgtpglpgvkghrgypgldgak

[0091] Gtpglpgvkghrgypgldgakgtpglpgvkghrgypgldgak

[0092] Gtpglpgvkghrgypgldgakgtpglpgvkghrgypgldgak

[0093] Gtpglpgvkghrgypgldgakgtpglpgvkghrgypgldgak

[0094] gtpglpgvkghrgypgldgakgtpglpgvkghrgypgldgak(SEQ ID NO.10);

[0095] (11) Amino acid sequence of HC2B-B7: gerglkghrgftglqglpgppgpsgdqgasgpagpsgprgerglkghrgftglqglpgppgpsgdqgasgpagpsgprgerglkghrgftglqglpgppgpsgdqgasgpagpsgprgerglkghrgftglqglpgppgpsgdqgasgpagpsgprgerglkghrgftglqglpgppgpsgdqgasgpagpsgprgerglkghrgftglqglpgppgpsgdqgasgpagpsgprgerglkghrgftglqglpgppgpsgdqgasgpagpsgprgerglkghrgftglqglpgppgpsgdqgasgpagpsgpr (SEQ ID NO.11, the underlined part is the repeating unit);

[0096] (12) Amino acid sequence of HC2B-B8: gerglkghrgftglqglpgppgpsgdqgasgpagerglkghrgftglqglpgppgpsgdqgasgpagerglkghrgftglqglpgppgpsgdqgasgpagerglkghrgftglqglpgppgpsgdqgasgpagerglkghrgftglqglpgppgpsgdqgasgpagerglkghrgftglqglpgppgpsgdqgasgpagerglkghrgftglqglpgppgpsgdqgasgpagerglkghrgftglqglpgppgpsgdqgasgpagerglkghrgftglqglpgppgpsgdqgasgpa (SEQ ID NO.12);

[0097] (13) Amino acid sequence of HC2B-B9: gerglkghrgftglqglpgppgpsgdqgerglkghrgftglqglpgppgpsgdqgerglkghrgftgl qglpgppgpsgdqgerglkghrgftglqglpgppgpsgdqgerglkghrgftglqglpgppgpsgdqgerglkghrgftglqglpgp pgpsgdqgerglkghrgftglqglpgppgpsgdqgerglkghrgftglqglpgppgpsgdqgerglkghrgftglqglpgppgpsg dqgerglkghrgftglqglpgppgpsgdqgerglkghrgftglqglpgppgpsgdqgerglkghrgftglqglpgppgpsgdq(SEQ ID NO.13);

[0098] (14) Amino acid sequence of HC2B-B10: gerglkghrgftglqglpgppgerglkghrgftglqglpgppgerglkghrgftglqglpgppgerglkghrgftglqglpgppgerglkghrgftglqglpgppgerglkghrgftglqglpgppgerglkghrgftglq glpgppgerglkghrgftglqglpgppgerglkghrgftglqglpgppgerglkghrgftglqglpgppgerglkghrgftglqglpgppgerglkghrgftglqglpgppgerglkghrgftglqglpgppgerglkghrgftglqglpgppgerglkg hrgftglqglpgppgerglkghrgftglqglpgpp (SEQ ID NO. 14).

[0099] 2. Insert the synthesized gene functional region into the pET-28a-Trx-His expression vector (as shown in Figure 9) to obtain the corresponding recombinant expression plasmid.

[0100] 3. Transform the successfully constructed expression plasmid into E. coli competent cells BL21 (DE3). The specific process is as follows: (1) Take out the E. coli competent cells BL21 (DE3) from the ultra-low temperature refrigerator and place them on ice. When they are half melted, take 2 μl of the plasmid to be transformed and add it to the E. coli competent cells BL21 (DE3) and mix it slightly 2-3 times. (2) Place the mixture on ice for 30 minutes, then heat shock it in a 42°C water bath for 45-90 seconds, take it out and place it on ice for 2 minutes. (3) Transfer it to a biological safety cabinet and add 700 μl of liquid LB culture medium, then incubate it at 37°C and 220 rpm for 60 minutes. (4) Take 200 μl of the bacterial solution and evenly spread it on an LB plate containing kanamycin sulfate (50 mg / L). (5) Incubate the plate in a 37°C incubator for 15-17 hours until colonies of uniform size grow.

[0101] 4. Pick 5-6 single colonies from the transformed LB plate and place them in a shake flask containing an antibiotic stock solution (ampicillin 100 mg / L). Incubate the culture in a shaker at 220 rpm and 37°C for a period of time until a haze appears. Cool the shake flask to 16-30°C and add IPTG (0.5 mM) to induce expression for a period of time. Then, divide the culture solution into centrifuge bottles and centrifuge at 6000 rpm and 4°C for 12 minutes. Collect the cells, record the cell weight, and take samples for electrophoresis.

[0102] 5. Resuspend the collected cells in a balanced working solution (200 mM NaCl, 25 mM Tris, 20 mM imidazole). Cool the culture to ≤15°C and homogenize twice or disrupt the cells by sonication. Collect the culture. Aliquot the disrupted cell suspension into centrifuge bottles and centrifuge at 17,000 rpm and 4°C for 30 min. Collect the supernatant.

[0103] 6. Recombinant humanized type II collagen was purified and enzymatically digested. The specific process was as follows: (1) Crude purification: a. Equilibration of the column: Use equilibration solution (200mM sodium chloride, 25mM Tris, 20mM imidazole) to equilibrate the column at a flow rate of 10mL / min. b. Loading: Add the supernatant after centrifugation to the column until the liquid has flowed away, at a flow rate of 5mL / min. c. Washing of impurities: Add 100mL of washing solution (200mM sodium chloride, 25mM Tris, 20mM imidazole) until the liquid has flowed away, at a flow rate of 10mL / min. d. Collect the target protein: add 20 mL of eluent (200 mM sodium chloride, 25 mM Tris, 250 mM imidazole) at a flow rate of 10 mL / min, collect the flow-through, and use UV-visible spectrophotometry to detect the protein concentration. Calculate the protein concentration according to the following formula (C (mg / ml) = A280 × dilution factor × extinction coefficient) and perform electrophoresis detection). e. Wash the column with 1 M imidazole working solution at a flow rate of 10 mL / min. (2) Enzyme digestion: Add TEV enzyme at a ratio of 20:1 between the total amount of protein and the total amount of TEV enzyme, and digest at 16°C for 2 h. Place the protein solution after digestion in a dialysis bag, dialyze at 4°C for 2 h, and then transfer to new dialysis solution (20 mM sodium chloride, 20 mM Tris) and dialyze overnight at 4°C. (3) Purification: a. Equilibrate the column: Use Solution A (20 mM Tris, 20 mM NaCl) to equilibrate the column at a flow rate of 10 ml / min. b. Load the sample: Load the sample at a flow rate of 5 ml / min, collect the flow-through sample, and perform electrophoresis. Store the protein at 4°C. c. Elute: Wash the column for 5 CV with Solution B (1 M NaCl, 20 mM Tris). d. Wash the column.

[0104] Test results:

[0105] The electrophoresis detection results involved in the preparation process of each recombinant protein are shown in Figures 1 to 7. Figure 1 shows the electrophoresis detection results of recombinant type II humanized collagen HC2B-a6 and HC2B-b5, showing that the expression level of the target protein after crude purification is low. Figure 2 shows the electrophoresis detection results of recombinant type II humanized collagen HC2B-a3, HC2B-b1, and HC2B-b3, showing that there are many impurities after crude purification and refined purification. Figure 3 shows the electrophoresis detection results of recombinant type II humanized collagen HC2B-A7 and HC2B-A8, showing that the expression level of the target protein after crude purification is low. Figure 3 also shows the electrophoresis detection results of recombinant type II humanized collagen B3Q, showing that the amount of protein after refined purification is low. Figure 4 shows the electrophoresis detection results of recombinant type II humanized collagen HC2B-A10, showing that the expression level of crude purified protein is high, the enzyme cleavage effect is good, and the protein purity after refined purification is high (the left and middle figures of Figure 4). Figures 4 and 7 also show the results of electrophoresis detection of recombinant type II humanized collagen HC2B-B9, which show that the expression level of crude pure protein is low, there are many miscellaneous bands, and the enzyme cleavage effect is poor. Figure 5 shows the results of electrophoresis detection of recombinant type II humanized collagen HC2B-A9, which shows that the expression level of crude pure protein is high, there are many miscellaneous bands, and the purity is low. The left figure of Figure 6 shows the results of electrophoresis detection of recombinant type II humanized collagen HC2B-B8, which shows that the expression level of crude pure protein is low, there are many miscellaneous bands, and no subsequent purification is performed. The right figure of Figure 6 and Figure 7 show the results of electrophoresis detection of recombinant type II humanized collagen HC2B-B7, which show that the expression level of crude pure protein is low, there are many miscellaneous bands, and the enzyme cleavage effect is poor. The middle figure of Figure 6 shows the electrophoresis detection of recombinant type II humanized collagen HC2B-B10, and the results show that the expression level of crude pure protein is low, there are many miscellaneous bands, and no subsequent purification is performed.

[0106] Therefore, in terms of expression, separation and purification effects, recombinant type II humanized collagen HC2B-A10 achieved the best effect compared with other recombinant type II humanized collagens.

[0107] Example 2: Bioactivity Detection of Recombinant Humanized Type II Collagen HC2B-A10

[0108] The method for detecting collagen activity can be found in the literature Juming Yao, Satoshi Yanagisawa, Tetsuo Asakura, Design, Expression and Characterization of Collagen-Like Proteins Based on the Cell Adhesive and Crosslinking Sequences Derived from Native Collagens, J Biochem. 136, 643-649 (2004). The specific implementation method is as follows:

[0109] (1) The concentration of the protein samples to be tested was detected by ultraviolet absorption method, including bovine type I collagen standard (Sigma, No.: 380002) and the recombinant type II humanized collagen HC2B-A10 (No. 015) with good purification and enzymatic cleavage effects provided by the present invention.

[0110] Specifically, the sample's UV absorbance at 215 nm and 225 nm is measured, and the protein concentration is calculated using the empirical formula C (μg / mL) = 144 × (A215 - A225). Note that the assay must be performed when A215 < 1.5. This method, which measures the characteristic absorption of peptide bonds under far-UV light, is unaffected by chromophore content, exhibits minimal interfering substances, and is simple to perform. It is suitable for detecting human collagen and its analogs, which do not develop color with Coomassie Brilliant Blue. (Reference: Walker JM. The Protein Protocols Handbook, second edition. Humana Press. 43-45.) After measuring the protein concentration, adjust the concentration of all tested proteins to 0.5 mg / mL with PBS.

[0111] (2) Add 100 μL of various protein solutions and a blank PBS solution as a control to a 96-well plate and let it stand at room temperature for 60 min.

[0112] (3) Add 10 5 3T3 cells in good culture condition were incubated at 37°C for 60 min.

[0113] (4) Wash each well 4 times with PBS.

[0114] (5) Detect the absorbance at OD492nm using the LDH detection kit (Roche, 04744926001). Calculate the cell adhesion rate based on the blank control value. The calculation formula is as follows: The cell adhesion rate reflects the activity of collagen. The higher the activity of the protein, the better the external environment it can provide to the cells in a short time, helping them to adhere to the wall.

[0115] The results are shown in Figure 8. This comparison demonstrates that the recombinant humanized type II collagen of the present invention exhibits superior bioadhesive activity compared to bovine type I collagen (B col I), with recombinant humanized type II collagen HC2B-A10 outperforming bovine type I collagen. Unexpectedly, the inventors demonstrated that eight repeats in the HC2B-A10 sequence ensured that the molecular weight of the recombinant humanized type II collagen was easily purified and stable, while exhibiting excellent bioadhesive activity.

[0116] Example 3: Mass spectrometry detection of recombinant humanized type II collagen HC2B-A10

[0117] Experimental methods

[0118] The recombinant humanized type II collagen HC2B-A10 with good purification and enzymatic cleavage effects provided by the present invention was subjected to mass spectrometry detection, and the specific process is as follows:

[0119] After DTT reduction and iodoacetamide alkylation, the protein sample was digested with trypsin overnight. The resulting peptides were desalted using a C18 ZipTip and then mixed with the matrix α-cyano-4-hydroxycinnamic acid (CHCA) and spotted on a plate. Finally, the peptides were analyzed using a matrix-assisted laser desorption ionization-time of flight mass spectrometer (MALDI-TOF / TOF Ulraflextreme). TM , Brucker, Germany for analysis (the technology of peptide fingerprinting can be found in Protein J. 2016; 35: 212-7).

[0120] Data retrieval was performed using the MS / MS Ion Search page on the local Masco website. Protein identification was based on the primary mass spectra of peptides generated after enzymatic digestion. Detection parameters: Trypsin digestion with two missed cleavage sites. Alkylation of cysteine ​​was set as a fixed modification. Oxidation of methionine was set as a variable modification. The NCBprot database was used for identification.

[0121] Table 1: Molecular weights and corresponding peptides detected by HC2B-A10 mass spectrometry

[0122] The coverage rate of the detected peptide functional regions is 100%

[0123] DNA sequence of HC2B-a3 (SEQ ID NO.16):

[0124] DNA sequence of HC2B-a6 (SEQ ID NO. 17):

[0125] DNA sequence of HC2B-b1 (SEQ ID NO. 18):

[0126] DNA sequence of HC2B-b3 (SEQ ID NO. 19):

[0127] DNA sequence of HC2B-b5 (SEQ ID NO. 20):

[0128] DNA sequence of B3Q (SEQ ID NO.21):

[0129] DNA sequence of HC2B-A7 (SEQ ID NO. 22):

[0130] DNA sequence of HC2B-A8 (SEQ ID NO. 23):

[0131] DNA sequence of HC2B-A9 (SEQ ID NO. 24):

[0132] DNA sequence of HC2B-A10 (SEQ ID NO. 25):

[0133] DNA sequence of HC2B-B7 (SEQ ID NO. 26):

[0134] DNA sequence of HC2B-B8 (SEQ ID NO. 27):

[0135] DNA sequence of HC2B-B9 (SEQ ID NO. 28):

[0136] DNA sequence of HC2B-B10 (SEQ ID NO. 29):

Claims

1. Collagen, comprising a plurality of repeating units, the repeating unit comprising the amino acid sequence shown in SEQ ID NO.15, the amino acid sequence obtained by mutation (substitution, insertion, deletion or addition) of one or more amino acid residues in the amino acid sequence of SEQ ID NO.15, or an amino acid sequence having 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity thereto, each repeating unit is directly connected or separated by one or more amino acid residues; preferably, the number of repeating units is 1-20; preferably, the number of repeating units is 6-10, such as 7, 8 or 9; preferably, the collagen comprises the amino acid sequence shown in SEQ ID NO.10, the amino acid sequence of SEQ ID NO. The amino acid sequence of NO.10 obtained by mutation (substitution, insertion, deletion or addition) of one or more amino acid residues, or a variant thereof having 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity thereto; preferably, the collagen is recombinant type II humanized collagen.

2. A polynucleotide encoding the collagen according to claim 1; preferably, the polynucleotide comprises the nucleotide sequence shown in SEQ ID NO.

29.

3. A nucleic acid comprising the polynucleotide according to claim 2, optionally further comprising nucleotides encoding a purification tag, such as a His tag, a GST tag, an MBP tag, a SUMO tag or a NusA tag, optionally further comprising nucleotides encoding a leader sequence.

4. A vector comprising a polynucleotide according to claim 2 or a nucleic acid according to claim 3, preferably wherein the vector is an expression vector, preferably wherein the vector comprises expression control elements such as a promoter, terminator and / or enhancer operably linked to the polynucleotide or nucleic acid.

5. A host cell comprising the polynucleotide according to claim 2, the nucleic acid according to claim 3 or the vector according to claim 4; preferably, the host cell is a bacterium, a fungus or an animal cell, preferably, the bacterium is Escherichia coli; preferably, the fungus is a yeast, such as Saccharomyces cerevisiae.

6. A method for producing collagen according to claim 1, comprising: (1) culturing the host cell according to claim 5 under suitable culture conditions; (2) harvesting host cells and / or culture medium containing collagen; and (3) Purify collagen.

7. A composition comprising the collagen according to claim 1, preferably, the composition is a kit; preferably, the composition is one or more of biological dressings, human bionic materials, plastic surgery materials, organoid culture materials, cardiovascular stent materials, coating materials, tissue injection filling materials, ophthalmic materials, obstetrics and gynecology biomaterials, nerve repair and regeneration materials, liver tissue materials and vascular repair and regeneration materials, 3D printing artificial organ biomaterials, cosmetic raw materials, pharmaceutical excipients and food additives, preferably, the composition is an injectable composition or an oral composition.

8. The composition according to claim 7, which is a composition for cartilage repair, preferably an injectable composition for cartilage repair.

9. A method for increasing cell adhesion, comprising contacting cells with the collagen according to claim 1, the polynucleotide according to claim 2, the nucleic acid according to claim 3, the vector according to claim 4, the host cell according to claim 5, and / or the composition according to claim 7 or 8.

10. Use of the collagen according to claim 1, the polynucleotide according to claim 2, the nucleic acid according to claim 3, the vector according to claim 4, the host cell according to claim 5, and / or the composition according to claim 7 or 8 in the preparation of a kit for increasing cell adhesion or cartilage repair, or in one or more of biological dressings, human bionic materials, plastic surgery materials, organoid culture materials, cardiovascular stent materials, coating materials, tissue injection filling materials, ophthalmic materials, obstetrics and gynecology biomaterials, nerve repair and regeneration materials, liver tissue materials and vascular repair and regeneration materials, 3D printing artificial organ biomaterials, cosmetic raw materials, pharmaceutical excipients and food additives.

Citation Information

Patent Citations

  • Polypeptides and their uses

    CN116715754B

  • Polypeptide, production method and uses thereof

    CN109293783A

  • Method for producing recombinant humanized II-type collagen single chain by using pichia pastoris

    CN110747198A

  • Cyclic polypeptide based on CII and application thereof

    CN110862450A

  • Recombinant I-type humanized collagen polypeptide as well as preparation method and application thereof

    CN113621052A

Cited By

  • Recombinant collagen and application thereof in prevention or treatment of virus infection

    CN120118178A